Titan Pharma Says FDA Clears IND Application For Nalmefene Implant

Titan Pharmaceuticals, Inc. (TTNP) announced Tuesday that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder (OUD).

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT